Researchers on the lookout for ways to help detect one of the world's deadliest cancers may have a new biomarker on their hands. In lung cancer patients, scientists have linked the presence in tumors of the protein C4d to a higher cancer mortality rate, a new study says.
A biomarker detectable in the breath of lung cancer patients holds promise for an accurate diagnostic, and researchers at the Cleveland Clinic have taken another stride toward making that a reality.
Biotech Clovis Oncology is tapping Qiagen's diagnostic expertise as it develops an EGFR-targeting lung cancer treatment, tasking the German company with creating a companion test that can identify patients for clinical trials and, eventually, be sold alongside the drug.
Using a bioinformatics method involving a computerized discovery pipeline, researchers have found a possible new treatment for a deadly kind of lung cancer from existing drugs--a little-used class of antidepressants already approved by the FDA.
Clinically effective but not cost-effective. That's what U.K. watchdogs have determined about Pfizer's targeted lung cancer drug, Xalkori. Despite a discount offer from Pfizer, the National Institute for Health and Care Excellence still believes Xalkori isn't a good value.
That makes two "breakthrough" tags for the Swiss drugmaker so far.
Lung cancer causes more deaths than any other cancer worldwide, and late diagnosis often contributes to high mortality rates. But now, researchers think they may have a key to spotting the disease earlier: a protein that's present in high levels in lung cancers and can be detected in the blood.
Eli Lilly's fight to extend Alimta exclusivity will drag into next year. As Reuters reports, a patent trial may have wrapped up last week, but both sides plan to file additional briefs through mid-December. At stake: 5 additional years of exclusivity on the blockbuster lung cancer treatment.
In the past, the U.K.'s cost-effectiveness gatekeeper has shown that it will bend preliminary draft guidance decisions if the price is right. But for Pfizer, which slashed costs on its targeted lung cancer drug Xalkori in hopes of gaining recommendation for its use in Britain's National Health Service, that price wasn't low enough.
Qiagen's string of companion diagnostics success continues with the FDA's approval of a molecular test for lung cancer, OK'd alongside a targeted Boehringer Ingelheim drug.